Regulation of bone-renal mineral and energy metabolism: The PHEX, FGF23, DMP1, MEPE ASARM pathway

Critical Reviews in Eukaryotic Gene Expression

Volumn 22, Issue 1, 2012, Pages 61-86

  Rowe, Peter S N ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

DMP1; FGF23; Kidney disease; KLOTHO; MEPE; Osteomalacia; PHEX; Rickets

Indexed keywords

DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; GLYCOPROTEIN; INSULIN; LEPTIN; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; PHOSPHATE; PHOSPHATE REGULATING GENE WITH HOMOLOGIES TO ENDOPEPTIDASES ON THE X CHROMOSOME PROTEIN; SEROTONIN; SHORT INTEGRIN BINDING LIGAND INTERACTING GLYCOPROTEIN; UNCLASSIFIED DRUG;

ACIDIC SERINE ASPARTATE RICH MEPE ASSOCIATED MOTIF; AUTOSOMAL RECESSIVE HYPOPHOSPHATEMIC RICKETS; BONE DEFECT; BONE MINERAL; BONE MINERALIZATION; CHROMOSOME 4Q; CHROMOSOME 5Q; CYTOKINE RELEASE; ENERGY METABOLISM; GENE MUTATION; HUMAN; KIDNEY CALCIFICATION; KIDNEY DISEASE; NONHUMAN; OSSIFICATION; OSTEOCYTE; OSTEOMALACIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN SECRETION; REVIEW; RICKETS;

AVES; DINOSAURIA; MUS; REPTILIA; TELEOSTEI; THEROPODA; VERTEBRATA;

EID: 84860321172     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v22.i1.50     Document Type: Review

References (201)

1. Burland C. An historic case of rickets: being an account of the medical examination of the remains of Princess Elizabeth, daughter of King Charles I., who died at Carrisbrooke Castle, September 8, 1650. Practitioner. 1918;100:391-5.
2. T.E.C. J. Princess Elizabeth, second daughter of King Charles 1, and rickets. Pediatrics. 1979;64(2):241.
3. O'Riordan JL. Rickets in the 17th century. J Bone Miner Res. 2006;21(10):1506-10.
4. Glisson F, Bate G, Regemorter A. A treatise of the rickets: being a disease common to children. London: Peter Cole, Cornhill Royal Exchange (Bedford Royal Infirmary Medical Library). 1651.
5. Rafter GW. Elmer McCollum and the disappearance of rickets. Perspect Biol Med. 1987;30(4):527-34.
6. Palm T. The geographical distribution and aetiology of rickets. Practitioner. 1890;45(270-279):321-42.
7. HYP-consortium, Francis F, Hennig S, Korn b, Reinhardt R, de Jong D, Poustka A, Lehrach H, Rowe PSN, Goulding JN, Summerfield T, Mountford RC, Read AP, Popowska E, Pronicka E, Davies KE, O'Riordan JLH, Econs MJ, Nesbitt T, Drezner MK, Oudet C, Pannetier S, Hanauer A, Strom TM, Meindl A, Lorenz B, Cagnoli M, Mohnike KL, Murken J, Meitinger T. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995;11(2):130-6.
8. Econs MJ, Francis F, Rowe PSN, Speer MC, O'Riordan JLH, Lehrach H, Becker PA. Dinucleotide repeat polymorphism at the DXS1683 locus. Hum Mol Genet. 1994;3(4):680.
9. Francis F, Strom TM, Hennig S, Boeddrich A, Lorenz B, Brandau O, Mohnike KL, Cagnoli M, Steffens C, Klages S, Borzym K, Pohl T, Oudet C, Econs MJ, Rowe PSN, Reinhardt R, Meitinger T, Lehrach H. Genomic organisation of the human PEX gene mutated in X-linked dominant hypophosphataemic rickets. Gen Res. 1997;7(6):573-85.
10. Rowe PSN. Molecular biology of hypophosphataemic rickets and oncogenic osteomalacia. Hum Genet 1994;94(5):457-67.
11. Rowe PSN. The role of the PHEX gene (PEX), in families with X-linked hypophosphataemic rickets. Curr Opin Nephrol Hyperten. 1998;7(4):367-76.
12. Rowe PSN. Finding mutations in disease genes. In: Econs MJ, editor. Genetics of osteoporosis and metabolic bone disease. 1 ed. Totowa, NJ: Humana Press; 2000. p. 431-46.
13. Rowe PSN, Francis F, Goulding J. Rapid isolation of DNA sequences flanking microsatellite repeats. Nucleic Acids Res 1994;22(23):5135-36.
14. Rowe PSN, Goulding J, Read A, Lehrach H, Francis F, Hanauer A, Oudet C, Biancalana V, Kooh SW, Davies KE, Oriordan JLH. Refining the genetic-map for the region flanking the X-linked hypophosphatemic rickets locus (Xp22.1-22.2). Hum Genet. 1994;93(3):291-4.
15. Rowe PSN, Goulding J, Read AP, Mountford RC, Hanauer A, Oudet C, Whyte MP, Meier-Ewert S, Lehrach H, Davies KE, O'Riordan JLH. New markers for linkage analysis of hypophosphataemic rickets. Hum Genet 1993;91:571-5.
16. Rowe PSN, Goulding JN, Francis F, Oudet C, Econs MJ, Hanauer A, Lehrach H, Read AP, Mountford RC, Summerfield T, Weissenbach J, Fraser W, Drezner MK, Davies KE, Oriordan JLH. The gene for X-linked hypophosphataemic rickets maps to a 200-300 kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE). Hum Genet. 1996;97(3):345-52.
17. Rowe PSN, Oudet C, Francis F, Sinding C, Pannetier S, Econs MJ, Strom TM, Meitinger T, Garabedian M, David A, Macher M-A, Questiaux E, Popowska E, Pronicka E, Read AP, Mokrzycki A, Glorieux FH, Drezner MK, Hanauer A, Lehrach H, Goulding J, O'Riordan JLH. Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet. 1997;6:539-49.
18. Rowe PSN, Read AP, Mountford RC, Benham F, Kruse TA, Camarino G, Davies KE, O'Riordan JLH. Three DNA markers for hypophosphataemic rickets. Hum Genet. 1992;89:539-42.
19. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics. 2000;67(1):54-68.
20. Rowe PSN, Ong A, Cockerill F, Goulding J, Hewison M. Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphataemic osteomalacia. Bone. 1996;18(2):159-69.
21. Rowe PSN. The wrickkened-pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med. 2004;15(5):264-81.
22. Liu S, Rowe PS, Vierthaler L, Zhou J, Quarles LD. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 2007;192(1):261-7.
23. Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology. 2008;149(4):1757-72.
24. Rowe PSN, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, Gutierrez GE. Surface Plasmon Resonance (SPR) confirms MEPE binds to PHEX via the MEPE-ASARM-motif: A model for impaired mineralization in X-linked rickets (HYP). Bone. 2005;36(1):33-46.
25. Addison W, Masica D, Gray J, McKee MD. phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res. 2009;25(4):695-705.
26. David V, Martin A, Hedge AM, Rowe PS. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology. 2009;150(9):4012-23.
27. Campos M, Couture C, Hirata IY, Juliano MA, Loisel TP, Crine P, Juliano L, Boileau G, Carmona AK. Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J. 2003;373(1):271-9.
28. Bresler D, Bruder J, Mohnike KL, Fraser D, Rowe PSN. Serum MEPE-ASARM-peptides are elevated in Xlinked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol. 2004;183:R1-9.
29. Rowe PS, Matsumoto N, Jo OD, Shih RN, Oconnor J, Roudier MP, Bain S, Liu S, Harrison J, Yanagawa N. Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone. 2006;39(4):773-86.
30. Guo R, Rowe PS, Liu S, Simpson LG, Xiao ZS, Quarles LD. Inhibition of MEPE cleavage by PHEX. Biochem Biophys Res Commun. 2002;297(1):38-45.
31. Rowe PSN, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone. 2004;34(2):303-19.
32. Addison W, Nakano Y, Loisel T, Crine P, McKee M. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite-an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res. 2008;23(10):1638-49.
33. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, Zelenchuk L, Evdokiou A, Findlay DM. Sclerostin is a locally acting regulator of late-osteoblast/ pre-osteocyte differentiation and regulates mineralization through a MEPE-ASARM dependent mechanism. J Bone Miner Res. 2011;27(7):1425-36
34. David V, Martin AC, Hedge AM, Drezner MK, Rowe PS. ASARM peptides: PHEX-dependent and independent regulation of serum phosphate. Am J Physiol Renal Physiol. 2011;300(3):F783-91.
35. Dobbie H, Unwin RJ, Faria NJ, Shirley DG. Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant. 2008;23(2):730-3.
36. Marks J, Churchill LJ, Edward SD, Unwin R. The phosphatonin matrix extracellular phosphoglycoprotein (MEPE) inhibits renal intestinal phosphate transport in vivo. J Am Soc Nephrol. 2008;19(12):2313-20.
37. Shirley DG, Faria NJ, Unwin RJ, Dobbie H. Direct micropuncture evidence that matrix extracellular phosphoglycoprotein inhibits proximal tubular phosphate reabsorption. Nephrol Dial Transplant. 2010; 25(10):3191-5.
38. Friedlander G. Welcome to MEPE in the renal proximal tubule. Nephrol Dial Transplant. 2010; 25(10):3135-6.
39. Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int. 2001;60(1):77-82.
40. Francis MD, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 1969;165(899):1264-6.
41. Goobes R, Goobes G, Shaw WJ, Drobny GP, Campbell CT, Stayton PS. Thermodynamic roles of basic amino acids in statherin recognition of hydroxyapatite. Biochemistry. 2007;46(16):4725-33.
42. Schlesinger DH, Hay DI. Complete covalent structure of statherin, a tyrosine-rich acidic peptide which inhibits calcium phosphate precipitation from human parotid saliva. J Biol Chem. 1977;252(5):1689-95.
43. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38(11):1310-5.
44. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Juppner H, Strom TM. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38(11):1248-50.
45. Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem. 2003;278(3):1998-2007.
46. Zmuda JM, Yerges-Armstrong LM, Moffett SP, Klei L, Kammerer CM, Roeder K, Cauley JA, Kuipers A, Ensrud KE, Nestlerode CS, Hoffman AR, Lewis CE, Lang TF, Barrett-Connor E, Ferrell RE, Orwoll ES. Genetic analysis of vertebral trabecular bone density and crosssectional area in older men. Osteoporosis international 2011;22(4):1079-90.
47. Jemtland R, Holden M, Reppe S, Olstad OK, Reinholt FP, Gautvik VT, Refvem H, Frigessi A, Houston B, Gautvik KM. Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J Bone Miner Res. 2011;26(8):1793-801.
48. Styrkarsdottir U, Halldorsson BV, Gudbjartsson DF, Tang NL, Koh JM, Xiao SM, Kwok TC, Kim GS, Chan JC, Cherny S, Lee SH, Kwok A, Ho S, Gretarsdottir S, Kostic JP, Palsson ST, Sigurdsson G, Sham PC, Kim BJ, Kung AW, Kim SY, Woo J, Leung PC, Kong A, Thorsteinsdottir U, Stefansson K. European bone mineral density loci are also associated with BMD in East-Asian populations. PLoS One. 2010;5(10):e13217. PMCID: 2951352.
49. Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, Hsu YH, Richards JB, Zillikens MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Grundberg E, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra B, Pastinen T, Pols HA, Sigurdsson G, Soranzo N, Thorleifsson G, Thorsteinsdottir U, Williams FM, Wilson SG, Zhou Y, Ralston SH, van Duijn CM, Spector T, Kiel DP, Stefansson K, Ioannidis JP, Uitterlinden AG. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet. 2009; 41(11): 1199-206
50. Kulkarni RN, Bakker AD, Everts V, Klein-Nulend J. Inhibition of osteoclastogenesis by mechanically loaded osteocytes: involvement of MEPE. Calcified Tissue Int. 2010;87(5):461-8. PMCID: 2964475.
51. Gluhak-Heinrich J, Pavlin D, Yang W, MacDougall M, Harris SE. MEPE expression in osteocytes during orthodontic tooth movement. Archiv Oral Biol. 2007;52(7):684-90. PMCID: 1868431.
52. Hayashibara T, Hiraga T, Sugita A, Wang L, Hata K, Ooshima T, Yoneda T. Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions. J Bone Miner Res. 2007;22(11):1743-51.
53. Harris SE, Gluhak-Heinrich J, Harris MA, Yang W, Bonewald LF, Riha D, Rowe PS, Robling AG, Turner CH, Feng JQ, McKee MD, Nicollela D. DMP1 and MEPE expression are elevated in osteocytes after mechanical loading in vivo: theoretical role in controlling mineral quality in the perilacunar matrix. J Musculoskelet Neuronal Interact 2007;7(4):313-5.
54. Nampei A, Hashimoto J, Hayashida K, Tsuboi H, Shi K, Tsuji I, Miyashita H, Yamada T, Matsukawa N, Matsumoto M, Morimoto S, Ogihara T, Ochi T, Yoshikawa H. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab. 2004;22(3):176-84.
55. Amir LR, Jovanovic A, Perdijk FB, Toyosawa S, Everts V, Bronckers AL. Immunolocalization of SIBLING and RUNX2 proteins during vertical distraction osteogenesis in the human mandible. J Histochem Cytochem. 2007;11:11.
56. Fukumoto S, Martin TJ. Bone as an endocrine organ. Trends Endocrinol Metab. 2009;20(5):230-6.
57. Kiela PR, Ghishan FK. Recent advances in the renalskeletal-gut axis that controls phosphate homeostasis. Lab Invest. 2009;89(1):7-14.
58. Confavreux CB, Levine RL, Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol. 2009;310(1-2):21-9.
59. David V, Martin A, Hedge AM, Rowe PS. PHEX & MEPE ASARM-motif regulate a novel bone-renal and fat-mass pathway (Abstract). J Bone Miner Res 2009;24 (Suppl 1). Abstract available from: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=d79d078c-e7b7-48de-ab35-83b08139efdd.
60. Petersen DN, Tkalcevic GT, Mansolf AL, RiveraGonzalez R, Brown TA. Identification of osteoblast/ osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. J Biol Chem. 2000;275(46):36172-80.
61. Argiro L, Desbarats M, Glorieux FH, Ecarot B. MEPE, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics. 2001;74(3):342-51.
62. Butler WT, Bhown M, Brunn JC, D'Souza RN, Farach-Carson MC, Happonen RP, Schrohenloher RE, Seyer JM, Somerman MJ, Foster RA, Tomana M, Van Dijk S. Isolation, characterization and immunolocalization of a 53-kDal dentin sialoprotein (DSP). Matrix. 1992;12(5):343-51.
63. Ritchie HH, Hou H, Veis A, Butler WT. Cloning and sequence determination of rat dentin sialoprotein, a novel dentin protein. J Biol Chem. 1994;269(5):3698-702.
64. Linde A, Bhown M, Butler WT. Noncollagenous proteins of dentin. A re-examination of proteins from rat incisor dentin utilizing techniques to avoid artifacts. J Biol Chem. 1980;255(12):5931-42.
65. MacDougall M, Simmons D, Luan X, Nydegger J, Feng J, Gu TT. Dentin phosphoprotein and dentin sialoprotein are cleavage products expressed from a single transcript coded by a gene on human chromosome 4. Dentin phosphoprotein DNA sequence determination. J Biol Chem. 1997;272:835-42.
66. Ritchie HH, Wang LH. Sequence determination of an extremely acidic rat dentin phosphoprotein. J Biol Chem. 1996;271(36):21695-8.
67. Yamakoshi Y, Hu JC, Fukae M, Zhang H, Simmer JP. Dentin glycoprotein: the protein in the middle of the dentin sialophosphoprotein chimera. J Biol Chem. 2005;280(17):17472-9.
68. Tsuchiya S, Simmer JP, Hu JC, Richardson AS, Yamakoshi F, Yamakoshi Y. Astacin proteases cleave dentin sialophosphoprotein (DSPP) to generate dentin phosphoprotein (Dpp). J Bone Min Res. 2011;26(1):220-8.
69. Bianchetti L, Oudet C, Poch O. M13 endopeptidases: new conserved motifs correlated with structure, and simultaneous phylogenetic occurrence of PHEX and the bony fish. Proteins. 2002;47(4):481-8.
70. Rawlings ND, Barrett AJ. MEROPS: the peptidase database. Nucleic Acids Res. 1999;27:325-31.
71. Turner AJ. Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. Biochem Soc Trans. 2003;31(Pt 3):723-7.
72. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays. 2001;23(3):261-9.
73. Fisher LW, Fedarko NS. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res. 2003;44 Suppl 1:33-40.
74. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun. 2001;280(2):460-5.
75. Machado JP, Johnson WE, O'Brien SJ, Vasconcelos V, Antunes A. Adaptive evolution of the Matrix Extracellular Phosphoglycoprotein in mammals. BMC Evol Biol. 2011;11(1):342.
76. Bardet C, Delgado S, Sire JY. MEPE evolution in mammals reveals regions and residues of prime functional importance. Cell Mol Life Sci. 2010;67(2):305-2.
77. Wang HG, Kawashima N, Iwata T, Xu J, Takahashi S, Sugiyama T, Suda H. MEPE activated by furin promotes pulpal cell adhesion. J Dent Res. 2011;90(4):529-34.
78. Sprowson AP, McCaskie AW, Birch MA. ASARM-truncated MEPE and AC-100 enhance osteogenesis by promoting osteoprogenitor adhesion. J Orthop Res. 2008;26(9):1256-62.
79. Gaucher C, Boukpessi T, Septier D, Jehan F, Rowe PS, Garabedian M, Goldberg M, Chaussain-Miller C. Dentin noncollagenous matrix proteins in familial hypophosphatemic rickets. Cells Tissues Organs. 2009;189(1-4):219-23.
80. Nagel DE, Khosla S, Sanyal A, Rosen DM, Kumagai Y, Riggs BL. A fragment of the hypophosphatemic factor, MEPE, requires inducible cyclooxygenase-2 to exert potent anabolic effects on normal human marrow osteoblast precursors. J Cell Biochem. 2004;93(6):1107-14.
81. Goldberg M, Lacerda-Pinheiro S, Jegat N, Six N, Septier D, Priam F, Bonnefoix M, Tompkins K, Chardin H, Denbesten P, Veis A, Poliard A. The impact of bioactive molecules to stimulate tooth repair and regeneration as part of restorative dentistry. Dent Clin North Am. 2006;50(2):277-98.
82. Liu H, Li W, Gao C, Kumagai Y, Blacher RW, DenBesten PK. Dentonin, a fragment of MEPE, enhanced dental pulp stem cell proliferation. J Dent Res. 2004;83(6):496-9.
83. Six N, Septier D, Chaussain-Miller C, Blacher R, Den-Besten P, Goldberg M. Dentonin, a MEPE fragment, initiates pulp-healing response to injury. J Dent Res. 2007;86(8):780-5.
84. Chen S, Chen L, Jahangiri A, Chen B, Wu Y, Chuang HH, Qin C, MacDougall M. Expression and processing of small integrin-binding ligand N-linked glycoproteins in mouse odontoblastic cells. Arch Oral Biol. 2008;53(9):879-89.
85. Boskey AL. Osteopontin and related phosphorylated sialoproteins: effects on mineralization. Ann N Y Acad Sci. 1995;760:249-56.
86. Boskey AL, Chiang P, Fermanis A, Brown J, Taleb H, David V, Rowe PS. MEPE's diverse effects on mineralization. Calcif Tissue Int. 2010;86(1):42-6.
87. Deshpande AS, Fang PA, Zhang X, Jayaraman T, Sfeir C, Beniash E. Primary structure and phosphorylation of dentin matrix protein 1 (DMP1) and dentin phosphophoryn (DPP) uniquely determine their role in biomineralization. Biomacromolecules. 2011;12(8):2933-45. PMCID: 3171794.
88. Boukpessi T, Gaucher C, Leger T, Salmon B, Le Faouder J, Willig C, Rowe PS, Garabedian M, Meilhac O, Chaussain C. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serineand aspartate-rich motif peptide in human hypophosphatemic dentin. Am J Pathol. 2010;177(2):803-12. PMCID: 2913338.
89. Boukpessi T, Septier D, Bagga S, Garabedian M, Goldberg M, Chaussain-Miller C. Dentin alteration of deciduous teeth in human hypophosphatemic rickets. Calcif Tissue Int. 2006;79(5):294-300
90. Jiang B, Cao Z, Lu Y, Janik CB, Lauziere S, Xie Y, Poliard A, Qin C, Ward LM, Feng JQ. DMP1 C-terminal mutant mice recapture the human ARHR tooth phenotype. J Bone Miner Res. 2010;25(10):2155-64.
91. Ogbureke KU, Fisher LW. Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int. 2005;68(1):155-66.
92. Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci U S A. 1998;95:5372-7.
93. Chau H, El-Maadawy S, McKee MD, Tenenhouse HS. Renal calcification in mice homozygous for the disrupted type IIa Na/Pi cotransporter gene Npt2. J Bone Miner Res. 2003;18(4):644-57.
94. Gupta A, Tenenhouse HS, Hoag HM, Wang D, Khadeer MA, Namba N, Feng X, Hruska KA. Identification of the type II Na(+)-Pi cotransporter (Npt2) in the osteoclast and the skeletal phenotype of Npt2-/mice. Bone. 2001;29(5):467-76.
95. Tenenhouse HS, Gauthier C, Chau H, St-Arnaud R. 1{alpha}-Hydroxylase gene ablation and Pi supplementation inhibit renal calcification in mice homozygous for the disrupted Na/Pi cotransporter gene Npt2a. Am J Physiol Renal Physiol. 2003;286(4):F675-81.
96. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47(3):312-8.
97. Michel F, Ambroisine ML, Duriez M, Delcayre C, Levy BI, Silvestre JS. Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation. 2004;109(16):1933-7.
98. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13(2):189-97.
99. Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita S, Nimura Y, Ishida J, Fukamizu A, Ikeda K. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res. 2009:24(3):241-50
100. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R. Angiotensin II accelerates osteoporosis by activating osteoclasts. Faseb J. 2008;22(7):2465-75.
101. de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol. 2011;22(9):1603-9. PMCID: 3171931.
102. Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest. 2008;118(2):722-34.
103. Martin A, Liu S, David V, Li H, Karydis A, Feng JQ, Quarles LD. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. Faseb J. 2011;25(8):2551-62.
104. Wu H, Teng PN, Jayaraman T, Onishi S, Li J, Bannon L, Huang H, Close J, Sfeir C. Dentin matrix protein 1 (DMP1) signals via cell surface integrin. J Biol Chem. 2011;286(34):29462-9. PMCID: 3190986.
105. Yuan B, Bowman S, Blank R, Lindberg I, Drezner MK. Mechanism of hexa-D-arginine curative effects on the HYP phenotype (abstract). J Bone Miner Res. 2011;26(Suppl 1):SA0032. Abstract available from: http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11007509-52&terms=.
106. Yuan B, Meudt J, Blank R, Feng J, Drezner MK. HexaD-arginine reversal of osteoblast 7B2 dysregulation in Hyp-mice normalizes the HYP biochemical phenotype (abstract). J Bone Miner Res. 2010;25(Suppl 1):(Presentation No: #1015). Abstract available from: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=c5c1b1c6-9d98-4ec8-bafa-833ec5088097.
107. Jain A, Fisher LW, Fedarko NS. Bone sialoprotein binding to matrix metalloproteinase-2 alters enzyme inhibition kinetics. Biochemistry. 2008;47(22):5986-95. PMCID: 2484124.
108. Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin-binding ligand N-linked glycoproteins (SIB-LINGs) bind and activate specific matrix metalloproteinases. FASEB J. 2004;18.(6):734-6.
109. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001;7(12):4060-6.
110. Karadag A, Fedarko NS, Fisher LW. Dentin matrix protein 1 enhances invasion potential of colon cancer cells by bridging matrix metalloproteinase-9 to integrins and CD44. Cancer Res. 2005;65(24):11545-52. PMCID: 1350722.
111. Karadag A, Ogbureke KU, Fedarko NS, Fisher LW. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v) beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst. 2004;96(12):956-65.
112. Eapen AS, Ramachandran A, George A. DPP activates integrin-mediated anchorage-dependent signals in undifferentiated mesenchymal cells. J Biol Chem. 2011.
113. Bleicher F, Couble ML, Buchaille R, Farges JC, Magloire H. New genes involved in odontoblast differentiation. Adv Dent Res. 2001;15:30-3.
114. Nakashima M, Iohara K, Ishikawa M, Ito M, Tomokiyo A, Tanaka T, Akamine A. Stimulation of reparative dentin formation by ex vivo gene therapy using dental pulp stem cells electrotransfected with growth/differentiation factor 11 (Gdf11). Hum Gene Ther. 2004;15(11):1045-53.
115. Alos N, Ecarot B. Downregulation of osteoblast PHEX expression by PTH. Bone. 2005;37(4):589-98.
116. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology. 2009;150 (11):4835-45.
117. Narayanan K, Ramachandran A, Hao J, He G, Park KW, Cho M, George A. Dual functional roles of dentin matrix protein 1. Implications in biomineralization and gene transcription by activation of intracellular Ca2+ store. J Biol Chem. 2003;278(19):17500-8.
118. Yuan B, Lin S, Cao Z, Liu Y, Lu Y, Drezner MK, Feng J. DMP1 does not function as a co-transcriptional factor (abstract). J Bone Miner Res 2011;26(Suppl 1):MO0112. Abstract available from: (http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A1100701-127&terms=).
119. Matsumoto N, Jo OD, Shih RN, Brochmann EJ, Murray SS, Hong V, Yanagawa J, Yanagawa N. Increased cathepsin D release by Hyp mouse osteoblast cells. Am J Physiol Endocrinol Metab. 2005;289(1):E123-32.
120. Matsumoto N, Jo OD, Shih RN, Yanagawa N. Altered cathepsin D metabolism in PHEX antisense human osteoblast cells. Biochem Biophys Res Commun. 2005;332(1):248-53.
121. Shih NR, Jo OD, Yanagawa N. Effects of PHEX antisense in human osteoblast cells. J Am Soc Nephrol. 2002;13(2):394-9.
122. Cho YD, Yoon WJ, Woo KM, Baek JH, Lee G, Cho JY, Ryoo HM. Molecular regulation of matrix extracellular phosphoglycoprotein expression by bone morphogenetic protein-2. J Biol Chem. 2009;284(37):25230.
123. Woo SM, Rosser J, Dusevich V, Kalajzic I, Bonewald LF. Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo. J Bone Miner Res. 2011;26(11):2634-46
124. Tu X, Rhee Y, Condon K, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI, Bellido T. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2011;50(1):209-17.
125. Lu Y, Yuan B, Qin C, Cao Z, Xie Y, Dallas SL, McKee MD, Drezner MK, Bonewald LF, Feng JQ. The biological function of DMP-1 in osteocyte maturation is mediated by its 57-kDa c-terminal fragment. J Bone Miner Res. 2011;26(2):331-40.
126. Gluhak-Heinrich J, Ye L, Bonewald LF, Feng JQ, MacDougall M, Harris SE, Pavlin D. Mechanical loading stimulates dentin matrix protein 1 (DMP1) expression in osteocytes in vivo. J Bone Miner Res. 2003;18(5):807-17.
127. Prie D, Torres PU, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int. 2009;4:1-8.
128. Alvarez-Diaz S, Larriba MJ, Lopez-Otin C, Munoz A. Vitamin D: proteases, protease inhibitors and cancer. Cell Cycle. 2010;9(1):32-7.
129. Bao BY, Yeh SD, Lee YF. 1α,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis. 2006;27(1):32-42.
130. Brage M, Abrahamson M, Lindstrom V, Grubb A, Lerner UH. Different cysteine proteinases involved in bone resorption and osteoclast formation. Calcified Tissue Int. 2005;76(6):439-47.
131. Danjo A, Yamaza T, Kido MA, Shimohira D, Tsukuba T, Kagiya T, Yamashita Y, Nishijima K, Masuko S, Goto M, Tanaka T. Cystatin C stimulates the differentiation of mouse osteoblastic cells and bone formation. Biochem Biophys Res Commun. 2007;360(1):199-204.
132. Dubois SG, Ruchon AF, Delalandre A, Boileau G, Lajeunesse D. Role of abnormal neutral endopeptidase-like activities in Hyp mouse bone cells in renal phosphate transport. Am J Physiol Cell Physiol. 2002;283(5):C1414-21.
133. Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest. 1985;75:1858-68.
134. Marie PJ, Travers R, Glorieux FH. Healing of bone lesions with 1,25-dihydroxyvitamin D3 in the young X-linked hypophosphataemic male mouse. Endocrinology. 1982;111:904-11.
135. Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab. 2010;95(4):1846-50. PMCID: 2853995.
136. Hoffman WH, Jain A, Chen H, Fedarko NS. Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome. Am J Med Genet A. 2008;146A(16):2164-8.
137. Bonjour JP, Trechsel U, Fleisch H, Schenk R, DeLuca HF, Baxter LA. Action of 1,25-dihydroxyvitamin D3 and a diphosphonate on calcium metabolism in rats. Am J Physiol. 1975;229(2):402-8.
138. Lawson-Matthew PJ, Guilland-Cumming DF, Yates AJ, Russell RG, Kanis JA. Contrasting effects of intravenous and oral etidronate on vitamin D metabolism in man. Clin Sci (Lond). 1988;74(1):101-6.
139. Loghman-Adham M, Dousa TP. Dual action of phosphonoformic acid on Na(+)-phosphate cotransport in opossum kidney cells. Am J Physiol. 1992;263(2 Pt 2):F301-10.
140. Loghman-Adham M, Szczepanska-Konkel M, Dousa TP. Phosphate transport in brush border membranes from uremic rats. Response to phosphonoformic acid. J Am Soc Nephrol. 1992;3(6):1253-9.
141. Loghman-Adham M, Szczepanska-Konkel M, Yusufi AN, Van Scoy M, Dousa TP. Inhibition of Na+-Pi cotransporter in small gut brush border by phosphonocarboxylic acids. Am J Physiol. 1987;252(2 Pt 1):G244-9.
142. McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone. 1987;8(Suppl 1):S35-41.
143. McCloskey EV, Yates AJ, Gray RE, Hamdy NA, Galloway J, Kanis JA. Diphosphonates and phosphate homeostasis in man. Clin Sci (Lond). 1988;74(6):607-12.
144. Muhlbauer RC, Bonjour JP, Fleisch H. Tubular handling of phosphate along the nephron of thyroparathyroidectomized rats injected with ethane-1-hydroxy-1,1-diphosphonate. Clin Sci (Lond). 1981;60(2):171-7.
145. Walton RJ, Russell RG, Smith R. Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man. Clin Sci Mol Med. 1975;49(1):45-56.
146. Stoll R, Fleisch H, Bonjour JP. Effect of diphosphonate treatment on phosphate transport by renal brush border vesicles. Am J Physiol. 1980;239(1):F13-6.
147. Szczepanska-Konkel M, Yusufi ANK, VanScoy M, Webster SK, Dousa TP. Phosphonocarboxylic acids as specific inhibitors of Na+-dependent transport of phosphate across renal brush border membrane. J Biol Chem. 1986;261:6375-83.
148. Trechsel U, Schenk R, Bonjour JP, Russell RG, Fleisch H. Relation between bone mineralization, Ca absorption, and plasma Ca in phosphonate-treated rats. Am J Physiol. 1977;232(3):E298-305.
149. VanScoy M, Loghman-Adham M, Onsgard M, Szczepanska-Konkel M, Homma S, Knox FG, Dousa TP. Mechanism of phosphaturia elicited by administration of phosphonoformate in vivo. Am J Physiol. 1988;255(5 Pt 2):F984-94.
150. Baum M, Moe OW, Zhang J, Dwarakanath V, Quigley R. Phosphatonin washout in Hyp mice proximal tubules: evidence for posttranscriptional regulation. Am J Physiol Renal Physiol. 2005;288(2):F363-70 Epub 2004 Sep 28.
151. Nesbitt T, Byun JK, Drezner MK. Normal phosphate transport in cells from the S2 and S3 segments of Hyp-mouse proximal renal tubules. Endocrinology. 1996;137:943-8.
152. Nesbitt T, Econs MJ, Byun JK, Martel J, Tenenhouse HS, Drezner MK. Phosphate transport in immortalized cell cultures from the renal proximal tubule of normal and Hyp mice: evidence that the HYP gene locus product is an extrarenal factor. J Bone Miner Res. 1995;10:1327-33.
153. Szczepanska-Konkel M, Yusufi AN, Dousa TP. Interactions of [14C]phosphonoformic acid with renal cortical brush-border membranes. Relationship to the Na+-phosphate co-transporter. J Biol Chem. 1987;262(17):8000-10.
154. Ullrich KJ, Rumrich G, Burke TR, Shirazi-Beechey SP, Lang H. Interaction of Alkyl/Arylphosphonates, phosphonocarboxylates and diphosphonates with different anion transport systems in the proximal renal tubule. J Pharmacol Exp Ther. 1997;283(3):1223-9.
155. Ecarot B, Desbarats M. 1,25-(OH)(2)D-3 down-regulates expression of Phex, a marker of the mature osteoblast. Endocrinology. 1999;140(3):1192-9.
156. Hines ER, Kolek OI, Jones MD, Serey SH, Sirjani NB, Kiela PR, Jurutka PW, Haussler MR, Collins JF, Ghishan FK. 1,25-dihydroxyvitamin D3 down-regulation of PHEX gene expression is mediated by apparent repression of a 110 kDa transfactor that binds to a polyadenine element in the promoter. J Biol Chem. 2004;279(45):46406-14
157. Steiglitz BM, Ayala M, Narayanan K, George A, Greenspan DS. Bone morphogenetic protein-1/Tolloid-like proteinases process dentin matrix protein-1. J Biol Chem. 2004;279(2):980-6.
158. von Marschall Z, Fisher LW. Dentin matrix protein-1 isoforms promote differential cell attachment and migration. J Biol Chem. 2008;283(47):32730-40. PMCID: 2583300.
159. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008;135(5):825-37. PMCID: 2614332.
160. Yadav VK, Oury F, Tanaka K, Thomas T, Wang Y, Cremers S, Hen R, Krust A, Chambon P, Karsenty G. Leptin-dependent serotonin control of appetite: temporal specificity, transcriptional regulation, and therapeutic implications. J Exp Med. 2011;208(1):41-52.
161. Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab. 2008;19(5):161-6.
162. Goltzman D. LRP5, serotonin and bone: complexity, contradictions and conundrums. J Bone Miner Res. 2011;26(9):2002-11
163. Cui Y, Niziolek PJ, Macdonald BT, Zylstra CR, Alenina N, Robinson DR, Zhong Z, Matthes S, Jacobsen CM, Conlon RA, Brommage R, Liu Q, Mseeh F, Powell DR, Yang QM, Zambrowicz B, Gerrits H, Gossen JA, He X, Bader M, Williams BO, Warman ML, Robling AG. Lrp5 functions in bone to regulate bone mass. Nature Med. 2011;17(6):684-91. PMCID: 3113461.
164. Price S. Bone: evidence for local effects of LRP5 on bone mass. Nat Rev Rheumatol. 2011;7(7):373.
165. Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res. 2010.
166. Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci. 2009;66(2):236-53.
167. Ubaidus S, Li M, Sultana S, de Freitas PH, Oda K, Maeda T, Takagi R, Amizuka N. FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. J Electron Microsc (Tokyo). 2009;58(6):381-92.
168. Rowe PS, Hedge AM, David V, Zelenchuk L. PHEX and Fat Energy Metabolism across a Bone-Renal Axis (Abstract) J Bone Miner Res. 2011;26(Suppl 1). Abstract available from: http://www.abstracts2view.com/asbmr/view.php?nu=ASBMR11L_A11007466-89&terms=.
169. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin Ddeficient rat in vivo. Endocrinology. 1986;119(1):84-90.
170. Cade C, Norman AW. Rapid normalization/stimulation by 1,25-dihydroxyvitamin D3 of insulin secretion and glucose tolerance in the vitamin D-deficient rat. Endocrinology. 1987;120(4):1490-7.
171. Capparelli AW, Roh D, Dhiman JK, Jo OD, Yanagawa N. Altered proximal tubule glucose metabolism in X-linked hypophosphatemic mice. Endocrinology. 1992;130(1):328-34.
172. Hruska KA, Rifas L, Cheng SL, Gupta A, Halstead L, Avioli L. X-linked hypophosphatemic rickets and the murine Hyp homologue. Am J Physiol. 1995;268:F35-F62.
173. Rifas L, Cheng S, Halstead LR, Gupta A, Hruska KA, Avioli LV. Skeletal casein kinase activity defect in the HYP mouse. Calcif Tissue Int. 1997;61:256-9.
174. Rifas L, Gupta A, Hruska KA, Avioli LV. Altered osteoblast gluconeogenesis in X-linked hypophosphatemic mice is associated with a depressed intracellular pH. Calcif Tissue Int. 1995;57(1):60-3.
175. Xie W, Mechin MC, Dubois SG, Lajeunesse D, van de Werve G. Up-regulation of liver glucose-6-phosphatase in x-linked hypophosphatemic mice. Horm Metab Res. 2002;34(6):288-92.
176. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003;17(3):509-11.
177. Hesse M, Frohlich LF, Zeitz U, Lanske B, Erben RG. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol. 2007;26(2):75-84.
178. Utsugi T, Ohno T, Ohyama Y, Uchiyama T, Saito Y, Matsumura Y, Aizawa H, Itoh H, Kurabayashi M, Kawazu S, Tomono S, Oka Y, Suga T, Kuro-o M, Nabeshima Y, Nagai R. Decreased insulin production and increased insulin sensitivity in the klotho mutant mouse, a novel animal model for human aging. Metabolism. 2000;49(9):1118-23.
179. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45-51.
180. Lorenzi O, Veyrat-Durebex C, Wollheim CB, Villemin P, Rohner-Jeanrenaud F, Zanchi A, U MV. Evidence against a direct role of klotho in insulin resistance. Pflugers Arch. 2010;459(3):465-73.
181. Drueke TB. Klotho, FGF23, and FGF receptors in chronic kidney disease: a yin-yang situation? Kidney Int. 2010;78(11):1057-60.
182. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53(5):875-83.
183. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24(2):382-91.
184. Kurokawa K, Rasmussen H. Ionic control of renal gluconeogenesis. IV. Effect of extracellular phosphate concentration. Biochim Biophys Acta. 1973;313(1):59-71.
185. Paula FJ, Plens AE, Foss MC. Effects of hypophosphatemia on glucose tolerance and insulin secretion. Horm Metab Res. 1998;30(5):281-4.
186. DeFronzo RA, Lang R. Hypophosphatemia and glucose intolerance: evidence for tissue insensitivity to insulin. N Engl J Med. 1980;303(22):1259-63.
187. Xie W, Li Y, Mechin MC, Van De Werve G. Up-regulation of liver glucose-6-phosphatase in rats fed with a P(i)-deficient diet. Biochem J. 1999;343 Pt 2:393-6. PMCID: 1220566.
188. Xie W, Tran TL, Finegood DT, van de Werve G. Dietary P(i) deprivation in rats affects liver cAMP, glycogen, key steps of gluconeogenesis and glucose production. Biochem J. 2000;352 Pt 1:227-32. PMCID: 1221451.
189. Winther K, Nybo M, Vind B, Pedersen SM, Hojlund K, Rasmussen LM. Acute hyperinsulinemia is followed by increased serum concentrations of fibroblast growth factor 23 in type 2 diabetes patients. Scand J Clin Lab Invest. 2011.
190. Duret L, Gasteiger E, Perriere G. LALNVIEW: a graphical viewer for pairwise sequence alignments. Comput Appl Biosci. 1996;12:507-10.
191. Huang X, Miller W, Schwartz S, Hardison RC. Parallelization of a local similarity algorithm. Comput Appl Biosci. 1992;8:155-65.
192. Huang XQ, Hardison RC, Miller W. A space-efficient algorithm for local similarities. Comput Appl Biosci. 1990;6:373-81.
193. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods. 2011;8(10):785-6.
194. Rice P. Programme Manual for the EGCG package. Cambridge, CB10 1RQ, England: Hinxton Hall; 1995.
195. Goldberg M, Six N, Chaussain C, DenBesten P, Veis A, Poliard A. Dentin extracellular matrix molecules implanted into exposed pulps generate reparative dentin: a novel strategy in regenerative dentistry. J Dent Res. 2009;88(5):396-9.
196. Hayashibara T, Hiraga T, Yi B, Nomizu M, Kumagai Y, Nishimura R, Yoneda T. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J Bone Miner Res. 2004;19(3):455-62.
197. Vordemvenne T, Paletta JR, Hartensuer R, Pap T, Raschke MJ, Ochman S. Cooperative effects in differentiation and proliferation between PDGF-BB and matrix derived synthetic peptides in human osteoblasts. BMC Musculoskelet Disord. 2011;12(1):263.
198. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A. 2008;105(13):5266-70. PMCID: 2278202.
199. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142(2):296-308. PMCID: 2910411.
200. Karsenty G, Oury F. The central regulation of bone mass, the first link between bone remodeling and energy metabolism. J Clin Endocrinol Metab. 2010;95(11):4795-801.
201. Zhou XJ, Fadda GZ, Perna AF, Massry SG. Phosphate depletion impairs insulin secretion by pancreatic islets. Kidney Int. 1991;39(1):120-8.